Birinyi Associates’s Regeneron Pharmaceuticals REGN Stock Holding History

Birinyi Associates’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2,075	Closed	-$1.48M	–	59
2024 Q4	$1.48M	Buy	+2,075	New	+$1.74M	0.41%	28
2017 Q3	–	Sell	-500	Closed	-$246K	–	91
2017 Q2	$246K	Buy	+500	New	+$219K	0.12%	85
2017 Q1	–	Sell	-1,000	Closed	-$367K	–	95
2016 Q4	$367K	Buy	1,000 +500	+100%	+$190K	0.21%	67
2016 Q3	$201K	Buy	+500	New	+$201K	0.11%	85
2016 Q2	–	Sell	-700	Closed	-$252K	–	81
2016 Q1	$252K	Sell	700 -500	-42%	-$206K	0.11%	74
2015 Q4	$651K	Buy	1,200 +700	+140%	+$379K	0.42%	54
2015 Q3	$233K	Buy	500 +50	+11%	+$26.9K	0.1%	83
2015 Q2	$230K	Buy	+450	New	+$220K	0.16%	78

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Birinyi Associates's REGN Position: Q1 2025 in Review

Birinyi Associates sold out of Regeneron Pharmaceuticals (REGN) in Q1 2025, closing a stake of 2,075 shares — an estimated $1.48M sold.

Birinyi Associates first reported a position in REGN in Q2 2015 and held it in 8 quarters. The position peaked at $1.48M in Q4 2024. 1,292 funds tracked by Wall St. Rank hold REGN as of Q1 2025.

Birinyi Associates reported no remaining Regeneron Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Birinyi Associates sold 2,075 Regeneron Pharmaceuticals shares in Q1 2025, an estimated $1.48M.
Birinyi Associates first reported a position in Regeneron Pharmaceuticals in Q2 2015 and held it in 8 quarters.
Birinyi Associates's Regeneron Pharmaceuticals position peaked at $1.48M in Q4 2024.
1,292 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2025.

Based on Birinyi Associates's 13F filing for Q1 2025, filed 5 May 2025.